Cargando…
Small molecule activators of the p53 response
Drugging the p53 pathway has been a goal for both academics and pharmaceutical companies since the designation of p53 as the ‘guardian of the genome’. Through growing understanding of p53 biology, we can see multiple routes for activation of both wild-type p53 function and restoration of mutant p53....
Autores principales: | Ladds, Marcus J G W, Laín, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478124/ https://www.ncbi.nlm.nih.gov/pubmed/30689917 http://dx.doi.org/10.1093/jmcb/mjz006 |
Ejemplares similares
-
Understanding p53 functions through p53 antibodies
por: Sabapathy, Kanaga, et al.
Publicado: (2019) -
Drugging in the absence of p53
por: Aning, Obed Akwasi, et al.
Publicado: (2019) -
The role of p53 in developmental syndromes
por: Bowen, Margot E, et al.
Publicado: (2019) -
Tumor suppressor p53 and metabolism
por: Liu, Juan, et al.
Publicado: (2018) -
Mutant p53 in colon cancer
por: Nakayama, Mizuho, et al.
Publicado: (2018)